What happened
China's National Medical Products Administration granted conditional approval for Aipusiwei (Eistewei tablets), the country's first innovative drug developed with AI assistance, for treating mild to moderate COVID-19 in adults.
The drug, developed by Westlake University, Westlake Laboratory, and Westlake Pharmaceuticals, took only three and a half years from discovery to clinical trial completion, with AI playing key roles in screening and data integration.
Following the approval, market attention has turned to 12 AI medical concept stocks with strong institutional ratings, including Mindray Medical, Hengrui Medicine, and Aier Eye Hospital.
Why it matters
This approval validates the feasibility and efficiency of AI-assisted drug development, potentially accelerating innovation in the pharmaceutical industry.
The AI medical market in China is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, a compound annual growth rate of 43.1%, signaling significant investment opportunities.
The success of Aipusiwei could encourage more companies to integrate AI into drug R&D, reshaping competitive dynamics in the healthcare sector.
Key facts
Aipusiwei is the first innovative drug in China approved for market with AI-assisted R&D.
The drug is indicated for adult patients with mild to moderate COVID-19.
The development process took three and a half years from source discovery to completion of clinical trials.
AI contributed to key stages, including screening from a DNA-encoded library containing 49 billion compounds.
A-share market has 37 AI medical concept stocks, with a combined market value exceeding 1 trillion yuan as of September 7.
Eight concept stocks have risen over 10% year-to-date, with BPS Bioscience leading at 53.90%.
14 AI medical concept stocks saw net profit growth in the first half of the year, with Dian Diagnostics reporting a 21.61-fold increase.
12 AI medical concept stocks have received 'positive' ratings from five or more institutions, with Mindray Medical having the most (32 institutions).
What to watch next
Monitor the commercial performance of Aipusiwei and its impact on the adoption of AI in drug development.
Watch for continued institutional interest and rating changes for the 12 highlighted concept stocks.
Track the growth trajectory of the AI medical market, particularly whether it meets the projected 43.1% CAGR.